Carvedilol Phosphate

×

Overview

What is Carvedilol Phosphate?

Carvedilol phosphate is a nonselective beta-adrenergic blocking agent with alpha-blocking activity. It is (2)-1-(9-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol phosphate salt (1:1) hemihydrate. It is a racemic mixture with the following structure:

Carvedilol phosphate is a white to almost-white solid with a molecular weight of 513.5 (406.5 carvedilol free base) and a molecular formula of CHNO•HPO•1/2 HO.

Carvedilol phosphate extended-release capsules are available for once-a-day administration as controlled-release oral capsules containing 10, 20, 40, or 80 mg carvedilol phosphate. Carvedilol phosphate extended-release hard gelatin capsules are filled with carvedilol phosphate controlled-release minitablets that are coated with methacrylic acid copolymers. Inactive ingredients include crospovidone, hypromellose, lactose monohydrate, magnesium stearate, methacrylic acid ethyl acrylate, methacrylic acid methyl methacrylate, microcrystalline cellulose, polyethylene glycol, propylene glycol, silicon dioxide, talc and triethyl citrate. The capsule shell contains gelatin and titanium dioxide. The 20 mg capsule shell also contains FD&C blue #1, FD&C yellow #5 and FD&C yellow #6. The 40 mg capsule shell also contains D&C yellow #10 and FD&C yellow #6. The 80 mg capsule shell also contains D&C yellow #10 and FD&C blue #1. The imprinting ink for the 10 mg, 40 mg and 80 mg contains D&C yellow #10 lake, FD&C blue #1, FD&C blue #2, FD&C red #40, iron oxide black, propylene glycol and shellac glaze. The imprinting ink for the 20 mg contains ammonium hydroxide, propylene glycol, shellac glaze, simethicone and titanium dioxide.

What does Carvedilol Phosphate look like?

What are the available doses of Carvedilol Phosphate?

Capsules: 10mg, 20mg, 40mg and 80 mg ()

What should I talk to my health care provider before I take Carvedilol Phosphate?

How should I use Carvedilol Phosphate?

Carvedilol phosphate extended-release capsules are an alpha-/beta-adrenergic blocking agent indicated for the treatment of:

Carvedilol phosphate extended-release capsules are intended for once-daily administration. Patients controlled with immediate-release carvedilol tablets alone or in combination with other medications may be switched to carvedilol phosphate extended-release capsules based on the total daily doses shown in .

Carvedilol phosphate extended-release capsules should be taken once daily in the morning with food. Carvedilol phosphate extended-release capsules should be swallowed as a whole capsule. Carvedilol phosphate extended-release capsules and/or its contents should not be crushed, chewed, or taken in divided doses.

What interacts with Carvedilol Phosphate?

Sorry No Records found

What are the warnings of Carvedilol Phosphate?

Sorry No Records found

What are the precautions of Carvedilol Phosphate?

Sorry No Records found

What are the side effects of Carvedilol Phosphate?

Sorry No records found

What should I look out for while using Carvedilol Phosphate?

Carvedilol phosphate extended-release capsules are contraindicated in the following conditions:

What might happen if I take too much Carvedilol Phosphate?

Overdosage may cause severe hypotension, bradycardia, cardiac insufficiency, cardiogenic shock, and cardiac arrest. Respiratory problems, bronchospasms, vomiting, lapses of consciousness, and generalized seizures may also occur.

The patient should be placed in a supine position and, where necessary, kept under observation and treated under intensive-care conditions. The following agents may be administered:

For excessive bradycardia:

To support cardiovascular function:

If peripheral vasodilation dominates, it may be necessary to administer adrenaline or noradrenaline with continuous monitoring of circulatory conditions. For therapy-resistant bradycardia, pacemaker therapy should be performed. For bronchospasm, beta-sympathomimetics (as aerosol or IV) or aminophylline IV should be given. In the event of seizures, slow IV injection of diazepam or clonazepam is recommended.

NOTE: In the event of severe intoxication where there are symptoms of shock, treatment with antidotes must be continued for a sufficiently long period of time consistent with the 7- to 10-hour half-life of carvedilol.

There is no experience of overdosage with carvedilol phosphate extended-release capsules. Cases of overdosage with carvedilol alone or in combination with other drugs have been reported. Quantities ingested in some cases exceeded 1,000 milligrams. Symptoms experienced included low blood pressure and heart rate. Standard supportive treatment was provided and individuals recovered.

How should I store and handle Carvedilol Phosphate?

Unopened vials of Gemcitabine for Injection, USP are stable until the expiration date indicated on the package when stored at controlled room temperature 20° to 25°C (68° to 77°F) and that allows for excursions between 15° and 30°C (59° and 86°F) [See USP Controlled Room Temperature] . Carvedilol phosphate extended-release capsules 10 mg are white opaque/white opaque capsules, imprinted MUTUAL 899. Available in:Carvedilol phosphate extended-release capsules 20 mg are dark green opaque/dark green opaque capsules, imprinted MUTUAL 900. Available in:Carvedilol phosphate extended-release capsules 40 mg are yellow opaque/yellow opaque capsules, imprinted MUTUAL 901. Available in:Carvedilol phosphate extended-release capsules 80 mg are green opaque/green opaque capsules, imprinted MUTUAL 902. Available in:Carvedilol phosphate extended-release capsules 10 mg are white opaque/white opaque capsules, imprinted MUTUAL 899. Available in:Carvedilol phosphate extended-release capsules 20 mg are dark green opaque/dark green opaque capsules, imprinted MUTUAL 900. Available in:Carvedilol phosphate extended-release capsules 40 mg are yellow opaque/yellow opaque capsules, imprinted MUTUAL 901. Available in:Carvedilol phosphate extended-release capsules 80 mg are green opaque/green opaque capsules, imprinted MUTUAL 902. Available in:Carvedilol phosphate extended-release capsules 10 mg are white opaque/white opaque capsules, imprinted MUTUAL 899. Available in:Carvedilol phosphate extended-release capsules 20 mg are dark green opaque/dark green opaque capsules, imprinted MUTUAL 900. Available in:Carvedilol phosphate extended-release capsules 40 mg are yellow opaque/yellow opaque capsules, imprinted MUTUAL 901. Available in:Carvedilol phosphate extended-release capsules 80 mg are green opaque/green opaque capsules, imprinted MUTUAL 902. Available in:Carvedilol phosphate extended-release capsules 10 mg are white opaque/white opaque capsules, imprinted MUTUAL 899. Available in:Carvedilol phosphate extended-release capsules 20 mg are dark green opaque/dark green opaque capsules, imprinted MUTUAL 900. Available in:Carvedilol phosphate extended-release capsules 40 mg are yellow opaque/yellow opaque capsules, imprinted MUTUAL 901. Available in:Carvedilol phosphate extended-release capsules 80 mg are green opaque/green opaque capsules, imprinted MUTUAL 902. Available in:

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Carvedilol is a racemic mixture in which nonselective beta-adrenoreceptor blocking activity is present in the S(–) enantiomer and alpha-adrenergic blocking activity is present in both R(+) and S(–) enantiomers at equal potency. Carvedilol has no intrinsic sympathomimetic activity.

Non-Clinical Toxicology

Carvedilol phosphate extended-release capsules are contraindicated in the following conditions:

Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, tranquilizers, etc.)

MAO inhibitors prolong and intensify the anticholinergic (drying) effects of antihistamines.

In clinical trials of carvedilol phosphate extended-release capsules in subjects with hypertension (338 subjects), the profile of adverse events observed with carvedilol phosphate was generally similar to that observed with the administration of immediate-release carvedilol. Therefore, the information included within this section is based on data from controlled clinical trials with carvedilol phosphate extended-release capsules as well as immediate-release carvedilol.

This product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible persons. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: